Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes
NCT ID: NCT00604656
Last Updated: 2017-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
241 participants
INTERVENTIONAL
2003-05-05
2004-01-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process
NCT01486914
Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes
NCT00564668
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes
NCT00676819
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes
NCT01173926
A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
NCT02131246
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin aspart
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Duration of diabetes for at least 12 months
* Treatment with insulin aspart for at least 3 months before trial start
* Body Mass Index (BMI) below 35.0 kg/m2
* HbA1c below 12.0%
Exclusion Criteria
* Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the investigator)
* Known hypoglycaemia unawareness as judged by the investigator
* Known hypersensitivity or allergy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Hradec Králové, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Bad Kreuznach, , Germany
Novo Nordisk Investigational Site
Bad Neuenahr-Ahrweiler, , Germany
Novo Nordisk Investigational Site
Diez, , Germany
Novo Nordisk Investigational Site
Frankfurt, , Germany
Novo Nordisk Investigational Site
Friedrichsthal, , Germany
Novo Nordisk Investigational Site
Karlsruhe, , Germany
Novo Nordisk Investigational Site
Marktheidenfeld, , Germany
Novo Nordisk Investigational Site
Marl, , Germany
Novo Nordisk Investigational Site
Oberursel, , Germany
Novo Nordisk Investigational Site
Rehlingen-Siersburg, , Germany
Novo Nordisk Investigational Site
Saarbrücken, , Germany
Novo Nordisk Investigational Site
Saint Ingbert, , Germany
Novo Nordisk Investigational Site
Simmern, , Germany
Novo Nordisk Investigational Site
Speyer, , Germany
Novo Nordisk Investigational Site
Würzburg, , Germany
Novo Nordisk Investigational Site
Budapest, , Hungary
Novo Nordisk Investigational Site
Nyíregyháza, , Hungary
Novo Nordisk Investigational Site
Cagliari, , Italy
Novo Nordisk Investigational Site
Chiavari, , Italy
Novo Nordisk Investigational Site
Città di Castello, , Italy
Novo Nordisk Investigational Site
Lucca, , Italy
Novo Nordisk Investigational Site
Orvieto, , Italy
Novo Nordisk Investigational Site
Parma, , Italy
Novo Nordisk Investigational Site
Perugia, , Italy
Novo Nordisk Investigational Site
Rimini, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Roma, , Italy
Novo Nordisk Investigational Site
Bytom, , Poland
Novo Nordisk Investigational Site
Mazowieckie, , Poland
Novo Nordisk Investigational Site
Radom, , Poland
Novo Nordisk Investigational Site
Warsaw, , Poland
Novo Nordisk Investigational Site
Wroclaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN2000-1542
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.